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INTRODUCTION
Lung cancer is a global epidemic and number
one killer among all cancers. Morbidity is high and
cure rate is only 13%. Many lung cancer patients
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are diagnosed in a relatively advanced stage, pre-
cluding radical resection (1). The increase in the
number of lung cancer deaths is mainly because it
is detected at a late stage. However, central type
early stage lung cancer has shown a good response
to endoscopic treatment (2-4).
To improve the detection rate of early bronchial
lesions, fluorescence diagnosis has been investi-
gated and used clinically in several facilities (5-7).
The principle of this diagnostic procedure is that
normal bronchial tissue emits green auto fluores-
cence (500-600 nm) excited by blue light, while tu-
mor or dysplasia lack green auto fluorescence be-
cause of differences in tissue architecture and auto
fluorescence fluorophores (8-10). Although the
value of fluorescence bronchoscopy in detecting
early lung cancer/pre-invasive lesions has been
evaluated in different clinical and research settings,
its role in the routine follow-up of PDT treated early
lung cancer has not been extensively evaluated.
The aim of this study was to objectively evaluate
the efficacy of autfluorescence bronchoscopy (SAFE-
3000) surveillance in PDT-treated early central lung
cancer patients. Longitudinal follow-up of these pa-
tients will be necessary to determine the impact of
fluorescence bronchoscopic surveillance in the iden-
tification of intraepithelial or invasive lesions. The
present study reviewed the use of auto fluorescence
bronchoscopy (SAFE-3000) during follow-up of
PDT-treated early lung cancer.
SUBJECTS AND METHODS
Patient selection
A retrospective study was conducted between De-
cember 1999 and August 2010, on 13 patients with
16 centrally located early lung cancer (CLELC)
lesions, have been treated by PDT and also been
followed-up after the PDT by the auto fluorescence
bronchoscopy (SAFE-3000). The patients had stan-
dard work up for lung cancer. Pretreatment exami-
nation included chest X-ray, bronchoscopy, auto
fluorescence bronchoscopy (SAFE-3000 or AFI)
Chest and abdominal computed tomography (CT),
brain magnetic resonance imaging (MRI) and/or
2-deoxy-2-[F-18] fluoro-D-glucose-positron emis-
sion tomography (FDG -PET)/CT. Assessment bron-
choscopy had been performed in all to evaluate
the extent, topography and the number of lesions
within the bronchial tree. All patients were staged
according to the lung cancer staging system of
International Union Against Cancer (UICC) (11).
Patients were considered candidates for PDT
under the following conditions : 1) histologically
proven squamous cell carcinoma 2) endoscopi-
cally visible distal tumor margins and accessibility
to laser irradiation. 3) tumor size2 cm. 4) no me-
tastasis in hilar or mediastinal lymph nodes and no
distant metastasis (stage 0 : TisNOM0 or stage I :
T1NOM0) using chest and abdominal CT, brain
MRI and/or PET/CT. 5) normal chest X-ray and
CT imaging cannot detect primary tumor and 6)
informed consent to undergo PDT was obtained.
Auto fluorescence Bronchoscope (SAFE-3000)
The newly developed video endoscopy-based auto
fluorescence (AF) bronchoscope system is referred
to as SAFE-3000 (12). In this system, normal bron-
chial tissue emits intense green auto fluorescence
when excited by blue light from a diode laser (408
nm), whereas abnormal tissue lacks the green auto
fluorescence due to the differences in the tissue
structure, metabolic state, and blood flow. SAFE-
3000 consists of a color CCD video endoscopy-
based auto fluorescence system with two light
sources, namely, a xenon lamp for white light (WL)
and a diode laser (408 nm) as an AF mode excita-
tion light source. Both white light (WL) mode and
AF mode appear at the same time on the screen.
WL findings were classified into two categories,
normal and abnormal in our protocol. “Normal find-
ing” means no visual abnormality. “Abnormal WL
finding” suggests irregularity of the bronchial mu-
cosa such as redness, hypervascularity, swelling,
thickening, as well as nodular or polypoid lesions.
Also, AF findings were classified into two catego-
ries, “normal sites” show green color images and
“abnormal sites” lack this green fluorescence and
show dark images.
PDT and follow-up
PDT procedures were performed using porfimer
sodium (Wyeth Japan KK ; Tokyo, Japan) or talapor-
fin sodium (Meiji Seika, Japan) and an Excimer
Dye Laser (Hamamatsu Photonics Co., Japan) or a
diode laser system (Matsushita Electric Industrial
Co., Japan) emitting continuous-wave laser light.
For patients till June 2004, porfimer sodium (2 mg/
kg) was given, 48 h before light irradiation. For pa-
tients after July 2004, talaporfin sodium (40 mg/m2)
was given 4 to 6 h before light irradiation. Laser
irradiation (664 nm) for the PDT was performed via
a quartz fiber inserted through the biopsy channel
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of the endoscope. The total energy of the laser ir-
radiation was 100 J/cm2, 150 mW/cm2, and the du-
ration of irradiation was usually 10 to 20 min.
Before the PDT, we performed SAFE-3000 with
a diode laser (408 nm) to define the base line fluo-
rescence intensity emitted from the tumor. After
the PDT, we performed SAFE-3000 to determine
the change in the intensity of fluorescence emitted
from the tumor as compared with that observed
before the PDT. Cytological and histological exami-
nations via fiber optic bronchoscope were performed
at 1, 2 and 3 months and thereafter at 3-month in-
tervals in the first year and 6-month intervals after
the second years after PDT. The antitumor effect
of the initial treatment was evaluated on the basis
of the change in the intensity of the fluorescence
emitted from the tumor after PDT compared with
that observed before the PDT, morphologic appear-
ance, and the findings on histopathologic examina-
tion of biopsy specimens. The tumors were then
classified as showing complete response (CR) (no
microscopically demonstrable tumor in brushing
and/or biopsy specimens over period of 4 weeks) ;
partial response (PR), showing a more than 50%
shrinkage of the lesion at endoscopy, but persistent
cancer at biopsy ; or no response (NR), that is a
less than 50% reduction in tumor size, or stable or
progressive disease. A second photodynamic treat-
ment was performed in cases of PR or NR. If a less
than complete response was obtained after a second
treatment, the patient was referred for surgical re-
section.
Pathological diagnosis
Biopsy specimens were taken from all suspicious
and abnormal lesions detected by AF bronchoscopy
and WL bronchoscopy and fixed in formalin and
embedded in paraffin. The pathological diagnoses
were coded according to the World Health Organi-
zation lung cancer classification (13). In the present
study, lesions in the bronchi were divided into the
following three categories according to histopa-
thological diagnosis ; 1) No malignancy : normal mu-
cosa, fibrosis of sub mucosa, goblet cell hyperplasia,
basal cell hyperplasia, 2) Premalignancy : Squamous
metaplasia and dysplasia, 3) Malignancy : Carci-
noma in situ and invasive cancer.
Statistical analysis
Data are presented as meanstandard deviation
(SD). The sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV)
of WL mode and AF mode of SAFE-3000 in detect-
ing premalignant and malignant lesions (based on
biopsy) were calculated. The relative sensitivity : the
ratio of the sensitivity of AF to WL was compared.
The Z-test was used to compare the diagnostic sen-
sitivity and specificity. A P value0.05 was consid-
ered statistically significant.
RESULTS
Patients’ characteristics
At the Tokushima University Hospital between
December 1999 and August 2010, 13 patients with
16 centrally located early lung cancers received
PDT. All patients were men (mean age, 70.25.34,
and range 57 - 76) and smokers or ex - smokers
(mean Brinkman index (1507.5953.95). The tu-
mors were detected on endoscopic screening of as-
ymptomatic high-risk patients or from symptomatic
patients’ complaints of haemoptysis or chronic
cough. Of these, 9 patients had previously under-
gone resection surgery for invasive lung cancer ;
most bronchoscopies were performed during post-
operative follow-up. All cases were squamous cell
carcinoma.
The Japanese Lung Cancer Society classifies
CLELCs on the basis of the endoscopic findings
into a thickened type, polypoid type, and nodular
type (14-17). The thickened type is characterized
by superficial lesions manifested by subtle mucosal
changes on the bronchial surface, and it is the pre-
dominant type (14-17). Of the 16 lesions examined
in this study, 11 of them were the thickened type,
4 lesions were nodular type and 1 was the poly-
poid type. Size of the tumors is ranged from 3-12
mm. The locations of the tumors are described in
Table 1.
PDT results
Of the 16 early carcinomas treated, 14 (87.5%)
had a CR, 2 (12.5%) had a NR after initial PDT.
Among the 14 carcinomas achieving a CR, 4 (29%)
recurred locally from 6 to 12 months after initial
PDT (Table. 2). The CR period until the last follow
up examination was between 3 to 60 months after
photodynamic therapy. A complete response that
lasted longer than 12 months after only one session
of PDT was observed in 7 of the 14 cancers (50%).
No severe early or late PDT-related sequelae were
noted. PDT was well tolerated by all patients.
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SAFE-3000 and histopathology findings after PDT
Over the period from December 1999 to August
2010, a total of 62 SAFE-3000 system bronchosco-
pies (average ; 4.5/patient) were performed on 13
patients who had undergone PDT for early cen-
tral lung cancer as part of the post-PDT fluores-
cence bronchoscopy surveillance at the University
of Tokushima. The follow-up time ranged from 1 to
60 months (median, 30 months) (Fig. 1). A total of
Table. 1. Tumors Characteristics.
Case Location Size(mm) Shape Histology* Stage Past History
1 Rt. B3 5 Swelling SCC Early Rt. lung cancer, Lobectomy
2 Lt. upper division br. Lt. B1+2 10 Nodular SCC Early Rt. lung cancer, Chemoradiation
Rt.B6 5 Redness
3 Rt. B6 8 Swelling SCC Early Rt. lung cancer, Lobectomy
4 Rt. B1, B2 spur 12 Redness SCC Early Rt. lung cancer, Lobectomy
5 Rt. main br. 8 Swelling SCC Early Left lung cancer, lobectomy,
6 Rt. B9 7 Ulcer SCC Early Bronchial cancer, Radiation
7 Lt. upper division br. Lt. B3 5 Nodular SCC Early Pulmonary emphysema
8 Lt. upper division br. 7 Swelling SCC Early Rt. lung cancer, Lobectomy
9 Middle, Basal br. spur 10 Swelling SCC Early None
10 Trachea 5 Nodular SCC Early Rt. lung cancer, Lobectomy
Carina 5 Nodular SCC Early
11 Rt. B10 a 3 Ulcer SCC Early Tuberculosis, Wedge resection
12 Rt. B6 8 Swelling SCC Early Rt. lung cancer, Lobectomy
13 Rt.B2 6 Polypoid SCC Early Rt. lung cancer, Lobectomy
Rt.B6 3 Swelling
*SCC : Squamous cell carcinoma
Table 2. Photodynamic therapy for early central lung cancer.
Patients Photosensitizer Fluence
dose
Number
of lesions
PDT
sessions
Complications Response Recuurence Follow-up
months
1 Porfimer sodium 235 1 1 No CR - 40
2 Porfimer sodium
Talaporfin sodium
450
140
2 2 No CR
CR
-
Recurrence
27
6
3 Porfimer sodium 300 1 1 No CR - 28
4* Porfimer sodium
Talaporfin sodium
250
400
1 2 No CR
CR
Recurrence
-
8
40
5 Porfimer sodium 400 1 1 No CR - 33
6 Talaporfin sodium 100 1 1 No CR - 15
7* Porfimer sodium
Talaporfin sodium
400
70
1 2 No CR
CR
Recurrence
Recurrence
12
8
8 Talaporfin sodium 150 1 1 No CR - 60
9 Talaporfin sodium 175 1 1 No CR - 15
10 Talaporfin sodium
Talaporfin sodium
100
100
2 2 No NR
NR
-
-
3
3
11 Talaporfin sodium 100 1 1 No CR Recurrence 12
12 Talaporfin sodium 100 1 1 No CR - 6
13 Talaporfin sodium
Talaporfin sodium
200
350
2 2 No CR
CR
-
-
3
3
CR : Complete response ; NR : No response.
*Case number 4 and 7 had one lesion which recieved two sessions of PDT.For case 4, CR occured after the first and the second
PDT then recurrence occured only after the first CR. For case number 7, CR occured after the first and the second PDT then recur-
rence occured after the first and the second CR.
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47 biopsies were carried out (average ; 4/patient).
The pathological diagnoses of these specimens
were as follow : normal epithelium in 12 (25.5%) ;
inflammation in 2 (4.25%) ; basal cell hyperplasia in
8 (17%) ; goblet cell hyperplasia in 4 (8.5%) ; fibro-
sis in 8 (17%) ; squamous dysplasia in 2 (4.25%) ;
squamous metaplasia in 4 (8.5%) and cancer in 7
(15%) (Table. 3) (Fig. 2). Thus, 13 biopsy speci-
mens (27.5%) were premalignant and malignant
lesions. WL alone correctly identified 9 of 13 (69%)
premalignant (squamous metaplasia, squamous dys-
plasia) and malignant (carcinoma in situ and inva-
sive cancer) lesions compared with 13 of 13 (100%)
premalignant and malignant lesions correctly iden-
tified by AF mode. The biopsy based sensitivity,
specificity, PPV and NPV of WL and AF mode in
post-PDT patients for both preinvasive and invasive
lesions are shown in Table. 4. The biopsy based
sensitivity of AF bronchoscopy to detect premalig-
nant and malignant lesions (100%) was significantly
higher than WL bronchoscopy alone (69%) (P=
0.0148). However, specificity value was superior in
WLB (P=0.0001). There was no statistically sig-
nificant difference in either PPV (P=0.2) or NPV
(P=0.07). However, NPV was superior in AF bron-
choscopy (100% vs. 86%). The sensitivity of SAFE-
3000 bronchoscopy for premalignant and malignant
(intraepithelial and invasive) lesions in post-PDT
patients far exceeded that of WLB, with a relative
sensitivity of SAFE-3000 vs. WLB of 145%. The ad-
dition of the fluorescence examination to conven-
tional WLB increased the sensitivity of post-PDT
surveillance from 69% to 100%.
Table. 3. Relationships between the bronchoscopic findings
and the pathological diagnoses of the biopsy specimens.
Histopathology(47) WLB SAFE-3000
Abnormal Normal Abnormal Normal
Normal(12) 3 9 0 12
Inflammation(2) 1 1 2 0
Basal cell hyperplasia(8) 2 6 7 1
Goblet cell hyperplasia(4) 1 3 3 1
Fibrosis(8) 2 6 8 0
Squamous metaplasia(4) 3 1 4 0
Squamous dysplasia(2) 2 0 2 0
Carcinoma(7) 4 3 7 0
Figure 1. N : Fluorescence bronchoscopy showed no abnor-
mal findings.: Fluorescence bronchoscopy showed fluorescence
defect in the treated lesion without histological evidence of ma-
lignancy.: Fluorescence bronchoscopy showed fluorescence
defect in the treated lesion with histological evidence of malig-
nancy. Arrows mean second PDT. Longitudinal axis : number
of samples, Horizontal axis : passage of time
Fig. 2A
Fig. 2B
Figure 2. Histopathology findings after PDT.
Fig.2 A : (A) Normal brobchial epithelium. (B) Basal cell hyper-
plasia. (C) Goblet cell hyperplasia. (D) Fibrosis.
Fig.2B : (A) Squamous metaplasia. (B) Squamous dysplasia. (C)
Carcinoma.
Tabel. 4. The sensitivity, specificity, PPV and NPV of WL and
AF mode in SAFE-3000.
Sensitivity Specificity PPV# NPV
WL 69% 73.5% 50% 86%
AF 100% 41% 39% 100%
P value 0.0148 0.0001 0.232 0.072
Z-test to compare between 2 proportions.
#PPV : Positive predictive value.
NPV : Negative predictive value.
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In 9 out of 14 lesions who presented complete re-
sponse after photodynamic therapy, the treated le-
sions finally recovered normal fluorescence, though
they temporary showed abnormal fluorescence in
some cases. CR cases that did not show normal
fluorescence were relapsed cases or a patient with
complete response whose treated lesion showed
fibrosis in the sub mucosa after two session pho-
todynamic therapy. Histopathological finding of the
complete response sites which demonstrated tem-
poral fluorescent defect consisted of inflammatory
lesions, goblet cell hyperplasia, basal cell hyperpla-
sia, squamous metaplasia or dysplasia (Table. 5).
Case presentation
Case 9 : 57 years old man. Flat elevated lesion
was noted in the membranous portion between the
right middle and lower lobes during bronchoscopy.
Fluorescence defect was observed during SAFE-
3000 of the same lesion (Fig. 3A, B). The result of
the biopsy was squamous cell carcinoma. PDT was
performed using Talaporfin sodium and laser (175 J).
Neoplastic lesion in bronchoscopy disappeared one
month after treatment ; fluorescence by SAFE-3000
was approved in the treated area (Fig. 3C, D).
SAFE-3000 follow up showed normal fluorescence
Figure 3. Bronchoscopic findings of the case 9. A : White light bronchoscopic finding of pre-PDT showed flatly elevated lesion in the
membranous portion between the middle lobe bronchus and the right basal bronchus. B : Fluorescence bronchoscopic finding of A
showed fluorescence defect at the same lesion. C : White light bronchoscopic finding at one month after PDT showed no tumorous lesion.
D : Fluorescence bronchoscopic finding of C showed no fluorescence defect. *Middle lobe bronchus. Arrows show the border of the
tumor.
Table. 5. Realtionship between PDT dose and Post-PDT histopathology.
Biopsy
Case PDT
Dose
1
month
3
month
6
month
9
month
12
month
18
month
24
month
30
month
36
month
1 235 normal
2 450 GH normal
140 GH Cancer
3 300 Inflammation GH normal normal
4 250 BH normal cancer
400 BH BH GH Fibrosis fibrosis Fibrosis Fibrosis fibrosis
5 400 Inflammation BH BH BH fibrosis Fibrosis Fibrosis
6 100 sq.metaplasia normal
7 400 sq.metaplasia sq.metaplasai sq. dysplasia cancer
70 BH BH cancer
8 150 sq.metaplasia sq.dysplasia normal
9 175 normal
10 100 cancer
100 cancer
11 100 normal cancer
12 100 normal
13 200 normal
350 normal
GH : Goblet cell hyperplasia ; BH : Basal cell hyperplasia ; sq.metaplasia : Squamous metaplasia ; sq,dysplasia : Squamous dysplasia.
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after PDT (Fig. 1 ; lesion 10).
Case 3 : 73 years old man. The chest radiograph
abnormality was noted when the patient referred
from another hospital complaining of cough. CT
scan showed a tumor in the right upper lobe, right
upper lobe resection was done with intraoperative
diagnosis of squamous cell carcinoma (pT2N0M0).
In addition, upon receiving postoperative follow up
bronchoscopy flat elevated lesion was pointed out
to the entrance of the right central portion B6. Fluo-
rescence defect was observed during SAFE-3000 of
the same lesion (Fig. 4A, B). The result of the bi-
opsy was squamous cell carcinoma. PDT was per-
formed using porfimer sodium and excimer laser
(300 J). Neoplastic lesions in the white light bron-
choscopy 5 months after treatment had disappeared,
SAFE-3000 showed fluorescence defect around B6
(Fig. 4C, D). The biopsy from fluorescence loss
site showed basement membrane thickening. 14
months after treatment, SAFE-3000 showed fluo-
rescence in the treated area (Fig. 4E, F). During
SAFE-3000 follow-up, fluorescence loss was ob-
served after PDT, followed by normal fluorescence
(Fig. 1 ; lesion 4).
Case 4 : 74 years old man. Abnormal right lung
shadow was found during preoperative evaluation
for orthopedic lumbar compression fracture surgery.
Detailed examination showed a large tumor about
5 cm in the right middle lobe. Another lesion was
found during bronchoscopy in the right upper lobe
bronchus (rtB1, 2 spur). Biopsy result was squamous
cell carcinoma. Middle lobectomy and lymph node
dissection (ND2a) was performed (pT2N0M0) for
middle lobe lesion. PDT was performed for the
lesion of the right upper lobe bronchus using por-
fimer sodium and Excimer Dye Laser (250 J). Re-
sidual lesion biopsy which was taken 8 months af-
ter treatment, showed recurrence. The second PDT
(400 J) was performed. No recurrence has been
noticed for 40 months. SAFE fluorescent is still
missing (Fig. 5A, B). The histopathology examina-
tion showed tissue fibrosis (Fig. 5C). SAFE-3000
follow-up showed normal fluorescence after PDT,
followed by fluorescence loss due to local recur-
rence. After second PDT, fluorescence is still miss-
ing due to fibrosis (Fig. 1 ; lesion 5).
Case 7 : 71 years old man. The patient had re-
ceived medical treatment for emphysema at age of
50. Home oxygen therapy was introduced at the age
of 65. The patient underwent regular bronchoscopy.
Elevated lesion was seen during inspection of Lt.B3
at the age of 71. The result of biopsy was squamous
cell carcinoma. Because of severe emphysema and
pulmonary hypertension, surgery was not consid-
ered. The PDT was performed by porfimer sodium
and excimer laser (400 J). Evidence of recurrence
was observed 12 months after treatment. The PDT
was performed again using talaporfin sodium and
laser (70 J). The tumor showed no obvious altera-
tion in white light bronchoscopy 3 months after the
second treatment. SAFE fluorescence loss was ob-
served in the treated area (Fig. 6A, B). The biopsy
showed bronchial epithelial hyperplasia and malig-
nant findings. Bronchoscopy showed a recurrence
8 months after the second treatment (Fig. 6C).
After PDT, SAFE-3000 showed fluorescence loss
Figure 4. Bronchoscopic findings of the case 3. A : White light
bronchoscopic finding of pre-PDT showed flatly elevated lesion
prior to the right B6. B : Fluorescence bronchoscopic finding of
A showed fluorescence defect at the site of the lesion. C : White
light bronchoscopic finding at 5 months after PDT showed no
tumorous lesion. D : Fluorescence bronchoscopic finding of C
showed fluorescence defect around the right B6. E : White light
bronchoscopic finding at 14 months after PDT showed no tumor-
ous lesion. D : Fluorescence bronchoscopic finding of E showed
no fluorescent defect around the right B6. *Right B6. Arrows
show the border of the tumor.
Figure 5. Bronchoscopic findings of the case 4. A : White light
bronchoscopic finding at 40 months after PDT showed no tumor-
ous lesion at the right upper bronchus where there had been a
tumor. B : Fluorescence bronchoscopic finding of A showed fluo-
rescence defect between the right B1 and B2 or B 3 . C : Histo-
pathological finding of biopsy specimen at the site of fluores-
cence defect showed no malignant change but fibrotic change
in the submucosa. *Right B 1.
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due local recurrence after first and second PDT
(Fig. 1 ; lesion 8).
DISCUSSION
Fluorescence diagnosis of the bronchial tree was
initially reported by Lam et al . and this diagnostic
procedure (LIFE system) has been adopted at sev-
eral sites in recent years, resulting in increased de-
tection rates of cancerous or precancerous lesions
by conventional bronchoscopy plus additional fluo-
rescence examination (6, 7, 18). Recently, Ikeda et
al . reported the feasibility of use of SAFE-3000 as a
very useful laser system for the early diagnosis of
centrally located early cancers (12). The potential
of AF bronchoscopy SAFE-3000 to follow up PDT
treated lesions in the central airways is uncertain.
This study was undertaken to evaluate a newly de-
veloped AF bronchoscopy (SAFE-3000) system as
a follow up tool for patients who underwent PDT
for early central lung cancer.
In the present study, we evaluated the role of
PDT as a curative treatment in early-stage, radi-
ologically node-negative early central carcinoma.
We obtained a high CR rate for in situ lesions. Of
the 16 early carcinomas treated, 14 (87.5%) had a
CR after initial PDT. Our results were comparable
with the response rates recorded in previous stud-
ies. Furukawa et al . (19) report CR and 5-year sur-
vival rates for patients with lesions1.0 cm of 92.8%
(77/83 patients) and 57.9%, respectively, and there
was a significant difference (P0.001) in the effi-
cacy of PDT in terms of response and recurrence
between lesionsor1 cm. A small study from the
Netherlands Cancer Institute, using i.v. Photofrin II,
showed a CR in 10/11 patients with stage I NSCLC
(20). Edell and Cortese (21) confirmed an impressive
CR rate (13/14 cases) obtained in tracheobronchial
tumors treated with hematoporphyrin-derivative
phototherapy. Of the 16 early carcinomas treated,
2 carcinomas had a NR after initial PDT. This le-
sion has granular shape and 0.5 cm diameter.
Additionally, recurrence after CR was recognized
in 4 of 14 CR lesions (29%) in the group of patients
with lesions1.0 cm in diameter. Despite the aver-
age diameter of the initial lesions being relatively
small (0.5 cm), recurrence was recognized within
12 months. Furukawa et al . (19) reported that recur-
rence after CR was recognized in 9 of 77 lesions
(11.7%) in the group of patients with lesions1.0
cm in diameter. Despite the average diameter of
the nine initial lesions being relatively small (0.46
cm), recurrence was recognized in eight of nine
lesions (88.9%) within 12 months. The reasons why
recurrences after CR were observed in the lesions
1.0 cm in diameter could be explained by inappro-
priate estimation of the peripheral margin in cases
of local recurrence at the site corresponding to the
peripheral margin and insufficient laser irradiation
or miss estimation of tumor depth in the cases of
local recurrence at the same site as the initial tu-
mor. In our study, we did not use endobronchial ul-
trasonography before PDT which is essential for es-
timation of tumor depth before PDT. The accuracy
of the initial evaluation of the lesion’s depth is un-
questionably fundamental to obtaining a better and
more durable clinical response to treatment. An-
other reason, the site of the tumor is very important
reason for recurrence, because difficult sites lead
to insufficient dose of laser radiation.
There is wide variation in the follow-up strategies
undertaken for post-PDT patients. Although chest
roentgenography, computed tomography, bone scan-
ning, bronchoscopy, sputum cytology were routinely
performed by some and totally ignored by others,
there are no specific guidelines suggested for post-
PDT patients. Advances in endoscopic technology
such as AF bronchoscopy have recently improved
the detection of premalignant and malignant bron-
chial lesions in high risk individuals. To date, nearly
all published AF bronchoscopy studies were done
for early detection of bronchial premalignant and
malignant lesions. No studies have evaluated the use
of the AF bronchoscopy after PDT for early central
lung cancer. Among AF bronchoscopies, we have
used SAFE-3000. The advantages of this PDD sys-
tem are as follows : increased sensitivity, ability to
clearly define the tumor margin, a color CCD video
endoscopy-based AF system equipped with a diode
Figure 6. Bronchoscopic findings of the case 7. A : White light
bronchoscopic finding at 3 months after second PDT showed
no tumorous lesion at left upper division bronchus where there
had been a tumor. B : Fluorescence bronchoscopic finding of A
showed large fluorescence defect at left upper division bronchus
though histopathological finding of biopsy specimen at the site
of fluorescent defect showed no malignant lesion. C : Broncho-
scopic finding at 8 months after second PDT showed recurrent
tumor at left upper division bronchus. *Left B3
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laser and a hand switch to easily switch between
the white light and AF modes. In the current study,
the biopsy based sensitivity and NPV of AF mode
were higher than WL mode. On the other hand, the
specificity of WL was significantly higher than AF.
In our study the relatively high sensitivity of AF
may be explained by due primarily to combination
technique of both modes in one procedure because
knowledge of white light-identified abnormalities
might influence the bronchoscopist to also call AF
identified abnormality in a given area. An impor-
tant limitation of AF may be the high rate of false
positive results which decrease the specificity and
PPV of AF examination and may lead to more bi-
opsies being evaluated at greater cost. Venman re-
ported that LIFE is slightly more sensitive (89%)
than white light alone (78%) in the diagnosis of dys-
plasia and CIS (7). However, in their report the
specificity and positive predictive value of LIFE was
lower (61 and 14%) than white light bronchoscopy
(88 and 32%). The reasons for false positives in our
study were mainly due to the thickened mucosal
layer due to basal or goblet cell hyperplasia and sub
mucosal layer due to chronic inflammation and fi-
brosis. Auto fluorescence emission was blocked by
the thickened layer of the bronchus in subjects with
chronic inflammation. It remains difficult to predict
pathological diagnosis from the observed grade of
auto fluorescence, as studies have found that some
lesions identified as class III turned out to be inflam-
matory lesions on biopsy (22, 23). Although the
specificity of AF in our study was statistically sig-
nificantly lower than that of WL, we do not think
that this difference is clinically relevant. The high
sensitivity and low specificity of AF is similar to
other imaging modalities such as low dose CT scan-
ning in the diagnosis of small malignant nodules
(24). There are many trials to increase the speci-
ficity. Quantitative fluorescence imaging or com-
bined fluorescence-reflectance imaging may also be
helpful in future bronchoscopic devices to address
specificity. As AF system has higher sensitivity com-
paring with WL, AF system can detect recurrence
after PDT early. AF system with higher NPV can
avoid unnecessary biopsy. If AF system shows nor-
mal green, there is no recurrence after PDT.
Little is known about the natural history of CR
carcinomas after PDT. Our data showed that in 9
out of 14 lesions who presented complete response
after photodynamic therapy, the treated lesions fi-
nally recovered normal fluorescence, though they
temporary showed abnormal fluorescence in some
cases. CR cases that did not show normal fluores-
cence were relapsed cases or a patient with com-
plete response whose treated lesion showed fibrosis
in the sub mucosa after two sessions of photody-
namic therapy. Histopathological finding of the com-
plete response sites which demonstrated temporal
fluorescent defect consisted of inflammatory le-
sions, goblet cell hyperplasia, basal cell hyperplasia,
squamous metaplasia or dysplasia. However, fibrotic
changes in sub mucosa give permanent fluorescent
defect. Since it is known that early-stage lung can-
cer even when successfully treated with photody-
namic therapy relapse, earlier detection of second
primaries and/or local recurrence by the use of
SAFE-3000 may expand the curative treatment op-
tions available to these patients. Careful mapping
of post-PDT lesions with SAFE-3000 may allow us
to better define the true rate of occurrence of these
lesions in post-PDT patients. In addition, longitu-
dinal monitoring with SAFE-3000 should help to
better characterize their natural history. These find-
ings strongly suggest that PDT treated carcinomas
could be carefully followed with SAFE-3000.
In conclusion, The AF videobronchoscopy system
(SAFE-3000) yields significantly higher sensitivity
for the assessment of PDT treated lung cancer than
WLB videobronchoscopy alone. Results of our study
suggest that AF bronchoscopy is an efficient tool
for follow up of PDT treated lung cancer. Further
studies of AF videobronchoscopy should be wid-
ened on examination of its use as follow up tool
after PDT.
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